Kennedy

BTIG Investment Banking Continues to Grow Debt Capital Advisory Team With John Bertrand

Retrieved on: 
Tuesday, August 1, 2023

BTIG announced today that John Bertrand has joined the firm as a Managing Director within Investment Banking’s Debt Capital Advisory Group.

Key Points: 
  • BTIG announced today that John Bertrand has joined the firm as a Managing Director within Investment Banking’s Debt Capital Advisory Group.
  • Based in the New York office, Mr. Bertrand will support the firm’s efforts to originate, structure, and execute debt financing for corporate issuers and financials sponsors.
  • Mr. Bertrand brings more than 25 years of industry experience to the firm.
  • “We are delighted to welcome John to BTIG,” said Anton LeRoy, President of BTIG.

PAUL KENNEDY NAMED VICE PRESIDENT, SPORTS COMMUNICATIONS AND SCOTT MARKLEY NAMED VICE PRESIDENT, STRATEGIC COMMUNICATIONS AT THE BIG TEN CONFERENCE

Retrieved on: 
Monday, July 10, 2023

ROSEMONT, Ill., July 10, 2023 /PRNewswire/ -- The Big Ten Conference has named Paul Kennedy vice president, sports communications and Scott Markley vice president, strategic communications.

Key Points: 
  • ROSEMONT, Ill., July 10, 2023 /PRNewswire/ -- The Big Ten Conference has named Paul Kennedy vice president, sports communications and Scott Markley vice president, strategic communications.
  • Effective August 7, 2023, Kennedy will oversee communications operations for all 28 Big Ten Conference-sponsored sports, while Markley will lead strategic communications and media relations across the Big Ten Conference.
  • Both Kennedy and Markley will report to deputy commissioner Diane Dietz and will be based at Big Ten Conference headquarters in Rosemont, Illinois.
  • Big Ten Conference names Paul Kennedy VP, sports communications and Scott Markley VP, strategic communications
    "I am thrilled to welcome Paul and Scott to the Big Ten Conference," Dietz stated.

Absci Reports Business Updates and First Quarter 2023 Financial and Operating Results

Retrieved on: 
Monday, May 15, 2023

VANCOUVER, Wash. and NEW YORK, May 15, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today reported financial and operating results for the quarter ended March 31, 2023.

Key Points: 
  • Achieved rapid advancements of generative AI drug creation platform, continually building on prior breakthroughs
    VANCOUVER, Wash. and NEW YORK, May 15, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today reported financial and operating results for the quarter ended March 31, 2023.
  • Revenue in the first quarter of 2023 was impacted by timing of progress on the Merck research collaboration based on administrative delays, and Absci expects to recognize revenues from this collaboration throughout 2023.
  • Net loss was $23.4 million for the first quarter of 2023, as compared to $29.5 million for the corresponding prior year period.
  • Absci continues to anticipate at least ten new Active Programs in 2023, based on the company's current partnership pipeline.

NASA Sets Coverage for Axiom Mission 2 Briefings, Events, Broadcast

Retrieved on: 
Friday, May 12, 2023

For the details and to RSVP, please contact the Axiom Space media team at: [email protected] .

Key Points: 
  • For the details and to RSVP, please contact the Axiom Space media team at: [email protected] .
  • NASA will broadcast the Ax-2 launch on NASA Television, the NASA app , and the agency's website .
  • Coverage will join the joint Axiom Space and SpaceX broadcast that begins at about 2:10 p.m. at:
    The broadcast will end after orbital insertion approximately 15 minutes after launch.
  • Leadership from NASA, Axiom Space, and SpaceX will participate in a postlaunch media briefing to provide an update on the launch and mission operations.

University of Oxford’s Kennedy Institute of Rheumatology Partners with Absci to Accelerate AI-Driven Immunotherapies

Retrieved on: 
Thursday, May 11, 2023

It takes an average of ten years and costs more than $1 billion to bring a new drug to market.

Key Points: 
  • It takes an average of ten years and costs more than $1 billion to bring a new drug to market.
  • Absci will use generative AI models with The Kennedy Institute’s genomics datasets to identify novel antibodies from patients with exceptional immune responses to inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis.
  • Then, using its reverse immunology approach, Absci will computationally re-assemble antigen-antibody pairs as promising potential starting points for drug development.
  • Absci and The Kennedy Institute will work together to accelerate the discovery and development of other promising drug targets and therapies.

NASA Invites Media to Next SpaceX Resupply Launch to Space Station

Retrieved on: 
Friday, May 5, 2023

WASHINGTON, May 5, 2023 /PRNewswire/ -- Media accreditation is open for SpaceX's 28th commercial resupply mission for NASA to the International Space Station.

Key Points: 
  • WASHINGTON, May 5, 2023 /PRNewswire/ -- Media accreditation is open for SpaceX's 28th commercial resupply mission for NASA to the International Space Station.
  • These solar panels, which roll out using stored kinetic energy, will expand the energy-production capabilities of the space station.
  • This will be the third set launching in the SpaceX Dragon's trunk, and once installed, will help provide a 20% to 30% increase in power for space station research and operations.
  • Media wishing to take part in person must apply for credentials at:
    Credentialed media will receive a confirmation email upon approval.

Textron Elects Thomas A. Kennedy to Board of Directors

Retrieved on: 
Wednesday, December 7, 2022

Textron Inc. (NYSE: TXT) announced that Thomas A. Kennedy has been elected to the companys Board of Directors, effective January 1, 2023.

Key Points: 
  • Textron Inc. (NYSE: TXT) announced that Thomas A. Kennedy has been elected to the companys Board of Directors, effective January 1, 2023.
  • Kennedy retired in June 2021 as the Executive Chairman of the Board of Directors of Raytheon Technologies, an aerospace and defense company that provides advanced systems and services for commercial, military and government customers globally.
  • View the full release here: https://www.businesswire.com/news/home/20221207005797/en/
    We are extremely fortunate to welcome Thomas Kennedy to our Board, said Textron Chairman and CEO Scott Donnelly.
  • Textron is known around the world for its powerful brands such as Bell, Cessna, Beechcraft, Hawker, Pipistrel, Jacobsen, Kautex, Lycoming, E-Z-GO, Arctic Cat, and Textron Systems.

Splashdown! NASA's Orion Returns to Earth After Historic Moon Mission

Retrieved on: 
Sunday, December 11, 2022

"The splashdown of the Orion spacecraft which occurred 50 years to the day of the Apollo 17 Moon landing is the crowning achievement of Artemis I.

Key Points: 
  • "The splashdown of the Orion spacecraft which occurred 50 years to the day of the Apollo 17 Moon landing is the crowning achievement of Artemis I.
  • During the mission, Orion performed two lunar flybys, coming within 80 miles of the lunar surface.
  • During re-entry, Orion endured temperatures about half as hot as the surface of the Sun at about 5,000 degrees Fahrenheit.
  • "Orion has returned from the Moon and is safely back on planet Earth," said Mike Sarafin, Artemis I mission manager.

Sabal Investment Holdings Grows Leadership Team; Focuses on Market-Specific Expertise

Retrieved on: 
Tuesday, November 29, 2022

IRVINE, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Sabal Investment Holdings (SIH) , a real estate investment management firm that serves institutional investors, today announced the expansion of its leadership team with the aim of driving the companys long-term strategy through distinct market expertise.

Key Points: 
  • IRVINE, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Sabal Investment Holdings (SIH) , a real estate investment management firm that serves institutional investors, today announced the expansion of its leadership team with the aim of driving the companys long-term strategy through distinct market expertise.
  • SIH Founder Pat Jackson will continue at the helm of the company as Chief Investment Strategist.
  • As Managing Director of Structured Credit at SIH, Ayres is responsible for structured credit investments, capital markets and portfolio management.
  • Headquartered in Irvine, Calif., Sabal Investment Holdings (SIH) is a real estate investment management firm with $ 1 billion AUM under management, providing advisory and investment management services to institutional investors.

Valo Health To Participate in Piper Sandler's 34th Annual Healthcare Conference

Retrieved on: 
Wednesday, November 16, 2022

BOSTON, Nov. 16, 2022 /PRNewswire/ -- Valo Health, Inc ("Valo") , the technology company focused on transforming the drug discovery and development process using human-centric data and artificial intelligence, today announced that its founder & CEO, David Berry, will present at Piper Sandler's 34th Annual Healthcare Conference at The Lotte New York Palace, New York, NY, on Thursday, December 1, 2022 at 8:10 AM (Kennedy 1, 4th Floor).

Key Points: 
  • BOSTON, Nov. 16, 2022 /PRNewswire/ -- Valo Health, Inc ("Valo") , the technology company focused on transforming the drug discovery and development process using human-centric data and artificial intelligence, today announced that its founder & CEO, David Berry, will present at Piper Sandler's 34th Annual Healthcare Conference at The Lotte New York Palace, New York, NY, on Thursday, December 1, 2022 at 8:10 AM (Kennedy 1, 4th Floor).
  • Valo Health, Inc ("Valo") is a technology company built to transform the drug discovery and development process using human-centric data and artificial intelligence driven computation.
  • As a digitally native company, Valo aims to fully integrate human-centric data across the entire drug development life cycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing costs, time, and failure rates.
  • Founded by Flagship Pioneering and headquartered in Boston, MA, Valo also has offices in Lexington, MA, New York, NY, Branford, CT, and San Francisco, CA.